Justin A. Ezekowitz
Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)

Justin A. Ezekowitz

Edmonton, AB, CA 
Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)
Edmonton, AB, CA 
OverviewLocationsClinical Research

Overview

Justin Ezekowitz practices in Edmonton, Canada. Mr. Ezekowitz is rated as a Distinguished expert by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Heart Failure, Heart Failure with Preserved Ejection Fraction (HFpEF), Atrial Fibrillation, Transcatheter Aortic Valve Replacement (TAVR), and Heart Bypass Surgery.

His clinical research consists of co-authoring 448 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 42 articles in the study of Heart Failure with Preserved Ejection Fraction (HFpEF).

Gender
Male

Locations

Edmonton, AB, Canada
Other Locations
AB, Canada
Calgary, AB, Canada
Toronto, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Evaluating the Clinical Efficacy of Resveratrol in Improving Metabolic and Skeletal Muscle Function in Patients With Heart Failure
Evaluating the Clinical Efficacy of Resveratrol in Improving Metabolic and Skeletal Muscle Function in Patients With Heart Failure
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Resveratrol
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency /and Sub-Study
A Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency /and Sub-Study
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: Ferric Carboxymaltose
Study Phase: Phase 3
The Long Term Effects of Dietary Sodium Restriction on Clinical Outcomes in Patients With Heart Failure
The Long Term Effects of Dietary Sodium Restriction on Clinical Outcomes in Patients With Heart Failure
Enrollment Status: Completed
Publish Date: January 31, 2023
Intervention Type: Other
Study Phase: Phase 3
The Need for FibEr Addition in SympTomatic Heart Failure
The Need for FibEr Addition in SympTomatic Heart Failure
Enrollment Status: Completed
Publish Date: August 18, 2022
Intervention Type: Dietary supplement
Study Phase: Not Applicable
High Versus Low SpO2 Oxygen Therapy in Patients With Acute Heart Failure
High Versus Low SpO2 Oxygen Therapy in Patients With Acute Heart Failure
Enrollment Status: Completed
Publish Date: April 26, 2019
High Versus Low SpO2 Oxygen Therapy in Patients With Acute Heart Failure
High Versus Low SpO2 Oxygen Therapy in Patients With Acute Heart Failure
Enrollment Status: Completed
Publish Date: November 06, 2018
Intervention Type: Other
Study Phase: Not Applicable
COMParison of Angiotensin Converting Enzyme Inhibitor managemenT Strategies Prior to Coronary Artery Bypass Surgery (the COMPACT Trial): a Pilot Randomized Controlled Registry Study
COMParison of Angiotensin Converting Enzyme Inhibitor managemenT Strategies Prior to Coronary Artery Bypass Surgery (the COMPACT Trial): a Pilot Randomized Controlled Registry Study
Enrollment Status: Completed
Publish Date: March 22, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

447 Total Publications

Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy.
Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy.
Journal: Circulation. Heart failure
Published: October 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ezekowitz's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 32 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile